Screening of anti-metastasis drugs by targeting angiopellosis and cancer cluster extravasation
Science Advances · 21.08.2026 · 12 (34)
DOI: 10.1126/sciadv.aed4204 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 21.08.2026. Verfasst von Xiao Cheng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Columbia University, New York, NY 10027, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neovascularization, Pathologic. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Metastasis accounts for 90% of cancer-related deaths. Extravasation is a necessary step for cancer metastasis. Currently, there are no drugs that specially target extravasation. Most cancer therapies target either proliferation or angiogenesis. We previously identified “angiopellosis” as the dominant mechanism by which vascular endothelial cells undergo conformational changes and actively “push” circulating cancer cells out of blood vessels. In this study, we developed an image-based high-throughput drug screening assay by coculturing cancer membrane–coated spheres with endothelial monolayers. Through this platform, we identified Bay 61-3606 as a lead angiopellosis inhibitor. Bay 61-3606 substantially reduced cancer cluster extravasation, an activity solely supported by angiopellosis and associated with higher metastatic potential, in both zebrafish and mouse models. Furthermore, Bay 61-3606 decreased distant metastases in murine models of lung carcinoma and triple-negative breast cancer. Mechanistically, Bay 61-3606 targeted the c-Jun amino-terminal kinase signaling pathway, down-regulating COL8A1 expression in endothelial cells and impairing the angiopellosis process.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, Columbia University, New York, NY 10027, USA.
- Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA.
- Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, and North Carolina State University, Raleigh, NC 27606, USA.
ORCID-Profile: Xiao Cheng, Mengrui Liu, Kaiyue Zhang, Zhang Yue, Dashuai Zhu, Zhenzhen Wang, Chao Lu, Na Yan, Brian S Henick, Ke Cheng
Förderung
- NHLBI NIH HHS
- NIH HHS
- NCI NIH HHS
- National Institutes of Health
Zitieren
APA
Cheng, X., Liu, M., Hu, S., Zhang, K., Yue, Z., Liu, S., Zhu, D., Wang, Z., Lu, C., Yan, N., Henick, B. S., & Cheng, K. (2026). Screening of anti-metastasis drugs by targeting angiopellosis and cancer cluster extravasation. Science Advances, 12(34). https://doi.org/10.1126/sciadv.aed4204
Vancouver
Cheng X, Liu M, Hu S, Zhang K, Yue Z, Liu S, et al. Screening of anti-metastasis drugs by targeting angiopellosis and cancer cluster extravasation. Science Advances. 2026;12(34). doi:10.1126/sciadv.aed4204
BibTeX
@article{Cheng2026,
author = {Cheng, Xiao and Liu, Mengrui and Hu, Shiqi and Zhang, Kaiyue and Yue, Zhang and Liu, Shuo and Zhu, Dashuai and Wang, Zhenzhen and Lu, Chao and Yan, Na and Henick, Brian S and Cheng, Ke},
title = {Screening of anti-metastasis drugs by targeting angiopellosis and cancer cluster extravasation},
journal = {Science Advances},
year = {2026},
volume = {12},
number = {34},
doi = {10.1126/sciadv.aed4204}
}
EUVIMED